Results 101 to 110 of about 15,765 (342)

Targeting the ARRDC3–DRP1 Axis via hUMSC‐Derived Exosomal CRYAB for Neuroprotection in Cerebral Ischemia/Reperfusion Injury

Advanced Healthcare Materials, EarlyView.
Intranasally administered hUMSC‐derived exosomes modulate the CRYAB–ARRDC3–Drp1 axis, alleviating mitochondrial dysfunction and ferroptosis, enhancing neuronal survival, reducing oxidative stress, and promoting functional recovery in ischemia‐reperfusion injury, offering a promising therapeutic strategy for ischemic stroke.
Rong ji, Zengyu Zhang, Zhuohang Liu, Kaicheng Yang, Xueyu Mao, Min Chu, Yong Wang, Jing Zhao   +7 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions [PDF]

, 2021
Nina Hanke, José David Gómez‐Mantilla, Naoki Ishiguro, Peter Stopfer, Valerie Nock   +4 more
openalex   +1 more source

Evaluating Cytocompatibility of Corynebacterium glutamicum‐poly Vinyl Alcohol Living Biomaterials for Ocular Use

Advanced Healthcare Materials, EarlyView.
In ophthalmology, living biomaterials such as living contact lenses appear promising for sustained drug delivery or biosensing. The cytocompatibility of Cg‐PVA hydrogels, developed as a model living contact lens, is investigated with the ocular surface, showing their potential translation to the clinic.
Krupansh Desai, Lorely Garcia‐Sanchez, Maryam Amini, Lara Luana Teruel‐Enrico, Silke Siegrist, Aránzazu del Campo, Sara Trujillo   +6 more
wiley   +1 more source

Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling

Frontiers in Pharmacology
A mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) model links the concentration-time profile of a drug with its therapeutic effects based on the underlying biological or physiological processes.
Keheng Wu, Xue Li, Zhou Zhou, Youni Zhao, Mei Su, Zhuo Cheng, Xinyi Wu, Zhijun Huang, Xiong Jin, Jingxi Li, Mengjun Zhang, Jack Liu, Bo Liu   +12 more
doaj   +1 more source

Dispelling urban myths about default uncertainty factors in chemical risk assessment - Sufficient protection against mixture effects? [PDF]

, 2013
© 2013 Martin et al.; licensee BioMed Central LtdThis article has been made available through the Brunel Open Access Publishing Fund.Assessing the detrimental health effects of chemicals requires the extrapolation of experimental data in animals to human
A Kortenkamp, A Kortenkamp, A Rane, AG Renwick, AG Renwick, AG Renwick, AG Renwick, AJ Lehman, Andreas Kortenkamp, BD Naumann, BD Naumann, BGH Bokkers, CI Bliss, CM Thompson, CS Weil, D Hattis, D Hattis, D Hattis, D Hattis, D Hattis, D Hattis, D Hattis, D Hattis, Danish EPA, DL Glaubiger, DM Sheehan, DW Gaylor, ECETOC, ECETOC, ECHA, EJ Bigwood, EJ Calabrese, EJ Calabrese, EJ Calabrese, EJ Calabrese, EJ Freireich, ER Homan, European Commission, European Community, F Kalberlah, F Kalberlah, F Kalberlah, G Charnley, G Ginsberg, G Ginsberg, G Ginsberg, G Ginsberg, G Vettorazzi, GA Skowronski, GN Krasovskii, GWM Petersvolleberg, H Boxenbaum, H Carlson-Lynch, HA Tilson, HJ Clewell, HJ Clewell, IPCS, IPCS, IPCS, IPCS, IPCS, IWF Davidson, JC Swartout, JECFA, JEFCA, JEFCA, JL Dorne, JLCM Dorne, K Schneider, K Schneider, K Schneider, K Walton, K Walton, K Walton, K Watanabe, KC Silverman, KEMI, KS Crump, KS Crump, LT Haber, M Dourson, M Faust, M Rennen, M Scholze, ME Meek, ML Dourson, ML Dourson, ML Dourson, National Research Council, National Research Council, Olwenn V Martin, P Griem, PR Gentry, PS Price, R Cooke, R Goble, R Hasegawa, R Hasegawa, R Kroes, R Scheuplein, R Truhaut, RH White, RL Dixon, SC Lewis, SCHER/SCENIHR/SCCS, Scholze Martin, SJS Baird, T Backhaus, TG Vermeire, TG Vermeire, USEPA, W Slob, W Slob, WJJ Hayes   +113 more
core   +1 more source

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, EarlyView.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial

Pharmaceutics
Physiologically based pharmacokinetic (PBPK) modelling for biologics, such as monoclonal antibodies and therapeutic proteins, involves capturing complex processes, including target-mediated drug disposition (TMDD), FcRn-mediated recycling, and tissue ...
Abdallah Derbalah, Tariq Abdulla, Mailys De Sousa Mendes, Qier Wu, Felix Stader, Masoud Jamei, Iain Gardner, Armin Sepp   +7 more
doaj   +1 more source

Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels [PDF]

Quantitative structure–activity relationship (QSAR) studies and mechanistic mathematical modeling approaches have been independently employed for analysing and predicting the transport and distribution of small molecule chemical agents in living ...
Bai, Jane
core   +1 more source

The utility of efavirenz-based prophylaxis against HIV infection. A systems pharmacological analysis [PDF]

, 2019
Pre-exposure prophylaxis (PrEP) is considered one of the five “pillars” by UNAIDS to reduce HIV transmission. Moreover, it is a tool for female self-protection against HIV, making it highly relevant to sub-Saharan regions, where women have the highest ...
Dickinson, Laura, Duwal, Sulav, Khoo, Saye, Kleist, Max von, Seeler, Daniel   +4 more
core   +4 more sources

Evaluating the Antiviral Efficacy of Encapsulated PKC Inhibitor BIM‐I against influenza A Virus Infection

Advanced Healthcare Materials, EarlyView.
This study explores nanoparticle delivery of the protein kinase C inhibitor bisindolylmaleimide‐I (BIM‐I) to combat influenza A virus infections. Encapsulation in biodegradable PLGA nanoparticles improved safety while maintaining the compound's strong antiviral activity.
Laura Klement, Jana Ismail, Josefine Schroeder, Amod Godbole, Johanna Schreiber, Christine Weber, Zoltan Cseresnyes, Marc T. Figge, Bettina Löffler, Ulrich S. Schubert, Stephanie Schubert, Christina Ehrhardt, Carsten Hoffmann   +12 more
wiley   +1 more source